Seminars in Hematology
Volume 41, Issue 3 , Pages 207-223 , July 2004

Recent advances in the molecular biology and immunobiology of chronic lymphocytic leukemia

  • Manlio Ferrarini

      Affiliations

    • Division of Medical Oncology C, Istituto Nazionale per la Ricerca sul Cancro, Genova, and Dipartmento di Oncologia Clinica e Sperimentale, Universitá di Genova, Genova, Italy
    • ,
  • Nicholas Chiorazzi

      Affiliations

    • North Shore-LIJ Research Institute and Departments of Medicine, North Shore University Hospital and NYU School of Medicine, Manhasset, NY, USA
    • Corresponding Author InformationAddress correspondence to Manlio Ferrarini, Istituto Nazionale per la Ricerca sul Cancro, IST Largo Rosanna Benzi, n. 10, 16132 Genova, Italy

References 

  1. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al.  A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1994. Blood. 1994;84:1361–1392
  2. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues (Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997). J Clin Oncol. 1999;17:3835–3849
  3. Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH, et al.  The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8:1640–1645
  4. Rai KR, Patel DV. Chronic lymphocytic leukemia. In:  Hoffman R,  Benz E,  Shattil S,  Furie B,  Cohen H,  Silberstein L editor. Hematology (Basic Principles and Practice). New York, NY: Churchill Livingstone; 1995;p. 1308–1321
  5. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia (Lessons learned from studies of the B cell antigen receptor). Annu Rev Immunol. 2003;21:841–894
  6. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis (Integrating molecular biologic insights into clinical practice for patients with CLL). Blood. 2004;103:1202–1210
  7. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–234
  8. Rai K. A critical analysis of staging in CLL. In:  Gail R,  Rai K editor. Chronic Lymphocytic Leukemia. Recent Progress and Future Directions. New York, NY: Liss; 1987;p. 253–260
  9. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al.  A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198–206
  10. Schroeder HW, Dighiero G. The pathogenesis of chronic lymphocytic leukemia (Analysis of the antibody repertoire). Immunol Today. 1994;15:288–294
  11. Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Allen SL, et al.  Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102:1515–1525
  12. Ghiotto F, Fais F, Albesiano E, Gaidano G, Allen SL, Kolitz JE, et al.  The light chain variable region gene repertoire of chronic lymphocytic leukemia B cells. J Clin Invest. 2004;113:1008–1016
  13. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–1847
  14. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–1854
  15. Maloum K, Davi F, Merle-Beral H, Pritsch O, Magnac C, Vuillier F, et al.  Expression of unmutated VH genes is a detrimental prognotic factor in chronic lymphocytic leukemia. Blood. 2000;96:377–379
  16. Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P, et al.  V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410–1416
  17. Lin K, Sherrington PD, Dennis M, Matrai Z, Cawley JC, Pettitt AR. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood. 2002;100:1404–1409
  18. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, et al.  Multivariate analysis of prognostic factors in CLL (Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors). Blood. 2002;100:1177–1184
  19. Zupo S, Isnardi L, Megna M, Massara R, Malavasi F, Dono M, et al.  CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood. 1996;88:1365–1374
  20. Ghia P, Guida G, Stella S, Gottardi D, Geuna M, Strola G, et al.  The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood. 2003;101:1262–1269
  21. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, et al.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002;99:1023–1029
  22. Chan AC, Iwashima M, Turck CE, Weiss A. ZAP-70 (A 70 kd protein-tyrosine kinase that associates with the TCR zeta chain). Cell. 1992;71:649–662
  23. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al.  Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639–1647
  24. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A, et al.  Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100:4609–4614
  25. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, et al.  ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944–4951
  26. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764–1775
  27. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, et al.  ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004;363:105–111
  28. MacLennan IC, Liu YJ, Oldfield S, Zhang J, Lane PJ. The evolution of B-cell clones. Curr Top Microbiol Immunol. 1990;159:37–63
  29. Weller S, Faili A, Garcia C, Braun MC, Le Deist FF, de Saint Basile GG, et al.  CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc Natl Acad Sci USA. 2001;98:1166–1170
  30. William J, Euler C, Christensen S, Shlomchik MJ. Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science. 2002;297:2066–2070
  31. Johnson TA, Rassenti LZ, Kipps TJ. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol. 1997;158:235–246
  32. Ghiotto F, Fais F, Valetto A, Albesiano E, Hashimoto S, Dono M, et al.  Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest. 2004;113:1008–1016
  33. Tobin G, Thunberg U, Johnson A, Thorn I, Soderberg O, Hultdin M, et al.  Somatically mutated Ig V(H)3–21 genes characterize a new subset of chronic lymphocytic leukemia. Blood. 2002;99:2262–2264
  34. Tobin G, Thunberg U, Johnson A, Eriksson I, Soderberg O, Karlsson K, et al.  Chronic lymphocytic leukemias utilizing the VH3–21 gene display highly restricted Vλ2–14 gene use and homologous CDR3s (Implicating recognition of a common antigen epitope). Blood. 2003;101:4952–4957
  35. Messmer BT, Albesiano E, Efremov DG, Ghiotto F, Allen SL, Kolitz J, et al.  Multiple distinct sets of stereotyped antigen receptors suggest a key promoting role for antigen in chronic lymphocytic leukemia. J Exp Med. 2004; (in press)
  36. Diaw L, Magnac C, Pritsch O, Buckle M, Alzari PM, Dighiero G. Structural and affinity studies of IgM polyreactive natural autoantibodies. J Immunol. 1997;158:968–976
  37. Dighiero G, Rose NR. Critical self-epitopes are key to the understanding of self-tolerance and autoimmunity. Immunol Today. 1999;20:423–428
  38. Briles DE, Nahm M, Schroer K, Davie J, Baker P, Kearney J, et al.  Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae. J Exp Med. 1981;153:694–705
  39. Ochsenbein AF, Fehr T, Lutz C, Suter M, Brombacher F, Hengartner H, et al.  Control of early viral and bacterial distribution and disease by natural antibodies. Science. 1999;286:2156–2159
  40. Broker BM, Klajman A, Youinou P, Jouquan J, Worman CP, Murphy J, et al.  Chronic lymphocytic leukemic cells secrete multispecific autoantibodies. J Autoimmun. 1988;1:469–481
  41. Sthoeger ZM, Wakai M, Tse DB, Vinciguerra VP, Allen SL, Budman DR, et al.  Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med. 1989;169:255–268
  42. Borche L, Lim A, Binet JL, Dighiero G. Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood. 1990;76:562–569
  43. Silverman GJ, Goldfien RD, Chen P, Mageed RA, Jefferis R, Goni F, et al.  Idiotypic and subgroup analysis of human monoclonal rheumatoid factors. Implications for structural and genetic basis of autoantibodies in humans. J Clin Invest. 1988;82:469–475
  44. Stevenson FK, Longhurst C, Chapman CJ, Ehrenstein M, Spellerberg MB, Hamblin TJ, et al.  Utilization of the VH4–21 gene segment by anti-DNA antibodies from patients with systemic lupus erythematosus. J Autoimmun. 1993;6:809–825
  45. Pugh-Bernard AE, Silverman GJ, Cappione AJ, Villano ME, Ryan DH, Insel RA, et al.  Regulation of inherently autoreactive VH4–34 B cells in the maintenance of human B cell tolerance. J Clin Invest. 2001;108:1061–1070
  46. Silverman GJ, Roben P, Bouvet JP, Sasano M. Superantigen properties of a human sialoprotein involved in gut-associated immunity. J Clin Invest. 1995;96:417–426
  47. Li Y, Spellerberg MB, Stevenson FK, Capra JD, Potter KN. The I binding specificity of human VH 4–34 (VH 4–21) encoded antibodies is determined by both VH framework region 1 and complementarity determining region 3. J Mol Biol. 1996;256:577–589
  48. Hivroz C, Geny B, Brouet JC, Grillot-Courvalin C. Altered signal transduction secondary to surface IgM cross-linking on B-chronic lymphocytic leukemia cells. Differential activation of the phosphatidylinositol-specific phospholipase C. J Immunol. 1990;144:2351–2358
  49. Michel F, Merle-Beral H, Legac E, Michel A, Debre P, Bismuth G. Defective calcium response in B-chronic lymphocytic leukemia cells. Alteration of early protein tyrosine phosphorylation and of the mechanism responsible for cell calcium influx. J Immunol. 1993;150:3624–3633
  50. Lankester AC, van Schijndel GM, van der Schoot CE, van Oers MH, van Noesel CJ, van Lier RA. Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells. Blood. 1995;86: 1090–1071
  51. Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood. 2003;101:1087–1093
  52. Zupo S, Cutrona G, Mangiola M, Ferrarini M. Role of surface IgM and IgD on survival of the cells from B-cell chronic lymphocytic leukemia. Blood. 2002;99:2277–2278
  53. Mangiola M, Cutrona G, Colombo M, Rossi E, Spriano M, Morabito F, et al.  Mechanisms that control cell apoptosis or survival through surface Ig in B-CLL. Leuk Lymphoma. 2003;44:S4
  54. Bernal A, Pastore RD, Asgary Z, Keller SA, Cesarman E, Liou HC, et al.  Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood. 2001;98:3050–3057
  55. Zupo S, Massara R, Dono M, Rossi E, Malavasi F, Cosulich ME, et al.  Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. Blood. 2000;95:1199–1206
  56. Dalla-Favera R, Gaidano G. In: Molecular Biology of Lymphomas. Philadelphia, PA: Lippincott; 2001;p. 2215–2235
  57. Jain R, Roncella S, Hashimoto S, Carbone A, Francia di Celle P, Foa R, et al.  A potential role for antigen selection in the clonal evolution of Burkitt’s lymphoma. J Immunol. 1994;153:45–52
  58. Roncella S, Cutrona G, Favre A, Ulivi M, Fais F, Signorini A, et al.  Apoptosis of Burkitt’s lymphoma cells induced by specific interaction of surface IgM with a self-antigen (Implications for lymphomagenesis in acquired immunodeficiency syndrome). Blood. 1996;88:599–608
  59. Panayiotidis P, Ganeshaguru K, Jabbar SA, Hoffbrand AV. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 1993;85:439–445
  60. Pu QQ, Bezwoda WR. Interleukin-4 prevents spontaneous in-vitro apoptosis in chronic lymphatic leukaemia but sensitizes B-CLL cells to melphalan cytotoxicity. Br J Haematol. 1997;98:413–417
  61. Francia di Celle P, Mariani S, Riera L, Stacchini A, Reato G, Foa R. Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. Blood. 1996;87:4382–4389
  62. Chaouchi N, Wallon C, Goujard C, Tertian G, Rudent A, Caput D, et al.  Interleukin-13 inhibits interleukin-2-induced proliferation and protects chronic lymphocytic leukemia B cells from in vitro apoptosis. Blood. 1996;87:1022–1029
  63. Trentin L, Cerutti A, Zambello R, Sancretta R, Tassinari C, Facco M, et al.  Interleukin-15 promotes the growth of leukemic cells of patients with B- cell chronic lymphoproliferative disorders. Blood. 1996;87:3327–3335
  64. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 1996;92:97–103
  65. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell’Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96:2655–2663
  66. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of “nurselike” cells that differentiate in the context of chronic lymphocytic leukemia. Blood. 2002;99:1030–1037
  67. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M, et al.  Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood. 2001;97:2777–2783
  68. Ibrahim S, Jilani I, O’Brien S, Rogers A, Manshouri T, Giles F, et al.  Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia. Cancer. 2003;97:1914–1919
  69. Pizzolo G, Chilosi M, Ambrosetti A, Semenzato G, Fiore-Donati L, Perona G, et al.  Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia. Blood. 1993;62:1289–1296
  70. Dameshek W. Chronic lymphocytic leukemia—An accumulative disease of immunolgically incompetent lymphocytes. Blood. 1967;29(suppl):566–584
  71. Fu SM, Winchester RJ, Feizi T, Walzer PD, Kunkel HG, et al.  Idiotypic specificity of surface immunoglobulin and the maturation of leukemic bone-marrow-derived lymphocytes. Proc Natl Acad Sci USA. 1974;71:4487–4490
  72. Deegan MJ, Abraham JP, Sawdyk M, Van Slyck EJ. High incidence of monoclonal proteins in the serum and urine of chronic lymphocytic leukemia patients. Blood. 1984;64:1207–1211
  73. Qian GX, Fu SM, Solanki DL, Rai KR. Circulating monoclonal IgM proteins in B cell chronic lymphocytic leukemia (Their identification, characterization and relationship to membrane IgM). J Immunol. 1984;133:3396–3400
  74. Sinclair D, Dagg JH, Mowat AM, Parrott DM, Stott DI. Serum paraproteins in chronic lymphocytic leukaemia. J Clin Pathol. 1984;37:463–466
  75. Fu SM, Chiorazzi N, Kunkel HG, Halper JP, Harris SR. Induction of in vitro differentiation and immunoglobulin synthesis of human leukemic B lymphocytes. J Exp Med. 1978;148:1570–1578
  76. Fu SM, Chiorazzi N, Kunkel HG. Differentiation capacity and other properties of the leukemic cells of chronic lymphocytic leukemia. Immunol Rev. 1979;48:23–44
  77. Chiorazzi N, Fu SM, Kunkel HG. Induction of human antibody responses in vitro with emphasis on allogeneic helper factors. Immunol Rev. 1979;45:219–241
  78. Totterman TH, Carlsson M, Nilsson K. Induction of IgM secretion by chronic B-lymphocytic leukaemia cells in serum-free medium (Effects of interferon-alpha, -gamma and phorbol ester). Clin Exp Immunol. 1988;71:187–192
  79. Totterman TH, Nilsson K, Simonsson B. Phorbol ester-induced production of beta-2-microglobulin in B-CLL cells (Relation to IgM secretory response and disease activity). Br J Haematol. 1986;62:95–103
  80. Rubartelli A, Sitia R, Zicca A, Grossi CE, Ferrarini M. Differentiation of chronic lymphocytic leukemia cells (correlation between the synthesis and secretion of immunoglobulins and the ultrastructure of the malignant cells). Blood. 1983;62:495–504
  81. Efremov DG, Ivanovski M, Batista FD, Pozzato G, Burrone OR. IgM-producing chronic lymphocytic leukemia cells undergo immunoglobulin isotype-switching without acquiring somatic mutations. J Clin Invest. 1996;98:290–298
  82. Fais F, Sellars B, Ghiotto F, Yan XJ, Dono M, Allen SL, et al.  Examples of in vivo isotype class switching in IgM+ chronic lymphocytic leukemia B cells. J Clin Invest. 1996;98:1659–1666
  83. Dono M, Hashimoto S, Fais F, Trejo V, Allen SL, Lichtman SM, et al.  Evidence for progenitors of chronic lymphocytic leukemia B cells that undergo intraclonal differentiation and diversification. Blood. 1996;87:1586–1594
  84. Gurrieri C, McGuire P, Zan H, Yan X-J, Cerutti A, Albesiano E, et al.  Chronic lymphocytic leukemia B cells undergo somatic hypermutation and intraclonal immunoglobulin VHDJH gene diversification. J Exp Med. 2002;196:629–639
  85. Honjo T, Kinoshita K, Muramatsu M. Molecular mechanism of class switch recombination (linkage with somatic hypermutation). Annu Rev Immunol. 2002;20:165–196
  86. Oppezzo P, Vuillier F, Vasconcelos Y, Dumas G, Magnac C, Payelle-Brogard B, et al.  Chronic lymphocytic leukemia B cells expressing AID display dissociation between class switch recombination and somatic hypermutation. Blood. 2003;101:4029–4032
  87. McCarthy H, Wierda WG, Barron LL, Cromwell CC, Wang J, Coombes KR, et al.  High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. Blood. 2003;101:4903–4908
  88. Albesiano E, Messmer BT, Damle RN, Allen SL, Rai KR, Chiorazzi N. Activation induced cytidine deaminase in chronic lymphocytic leukemia B cells (Expression as multiple forms in a dynamic, variably sized fraction of the clone). Blood. 2003;102:3333–3339
  89. Marti GE, Zenger V, Caproaso NE, Brown M, Washington GC, Carter P, et al.  Antigenic expression of B-cell chronic lymphocytic leukemic lymphocytes. Anal Quant Cytol Histol. 1989;11:315–323
  90. Trentin L, Zambello R, Sancetta R, Facco M, Cerutti A, Perin A, et al.  B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. Cancer Res. 1997;57:4940–4947
  91. Damle RN, Ghiotto F, Valetto A, Albesiano E, Fais F, Yan XJ, et al.  B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood. 2002;99:4087–4093
  92. van Oers MH, Pals ST, Evers LM, van der Schoot CE, Koopman G, Bonfrer JM, et al.  Expression and release of CD27 in human B-cell malignancies. Blood. 1993;82:3430–3436
  93. Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood. 1995;85:3556–3565
  94. Bigler RD, Bushkin Y, Chiorazzi N. S152 (CD27). A modulating disulfide-linked T cell activation antigen. J Immunol. 1988;141:21–28
  95. Tangye SG, Liu YJ, Aversa G, Phillips JH, de Vries JE. Identification of functional human splenic memory B cells by expression of CD148 and CD27. J Exp Med. 1998;188:1691–1703
  96. Agematsu K, Nagumo H, Yang FC, Nakazawa T, Fukushima K, Ito S, et al.  B cell subpopulations separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoglobulin production. Eur J Immunol. 1997;27:2073–2079
  97. Agematsu K, Nagumo H, Shinozaki K, Hokibara S, Yasui K, Terada K, et al.  Absence of IgD-CD27(+) memory B cell population in X-linked hyper-IgM syndrome. J Clin Invest. 1998;102:853–860
  98. Freedman AS, Freeman G, Whitman J, Segil J, Daley J, Levine H, et al.  Expression and regulation of CD5 on in vitro activated human B cells. Eur J Immunol. 1989;19:849–855
  99. Werner-Favre C, Vischer TL, Wohlwend D, Zubler RH. Cell surface antigen CD5 is a marker for activated human B cells. Eur J Immunol. 1989;19:1209–1213
  100. Zupo S, Dono M, Massara R, Taborelli G, Chiorazzi N, Ferrarini M. Expression of CD5 and CD38 by human CD5- B cells (requirement for special stimuli). Eur J Immunol. 1994;24:1426–1433
  101. Allsopp RC, Chang E, Kashefi-Aazam M, Rogaev EI, Piatyszek MA, Shay JW, et al.  Telomere shortening is associated with cell division in vitro and in vivo. Exp Cell Res. 1995;220:194–200
  102. Nilsson P, Mehle C, Remes K, Roos G. Telomerase activity in vivo in human malignant hematopoietic cells. Oncogene. 1994;9:3043–3048
  103. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA. 1995;92:9082–9086
  104. Engelhardt M, Albanell J, Drullinsky P, Han W, Guillem J, Scher HI, et al.  Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma. Clin Cancer Res. 1997;3:1849–1857
  105. Damle RN, Batliwalla FM, Ghiotto F, Valetto A, Albesiano E, Sison C, et al.  Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood. 2004;103:375–382
  106. Hultdin M, Rosenquist R, Thunberg U, Tobin G, Norrback KF, Johnson A, et al.  Association between telomere length and V(H) gene mutation status in chronic lymphocytic leukaemia (Clinical and biological implications). Br J Cancer. 2003;88:593–598
  107. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia (analysis of its prognostic significance). Br J Haematol. 1986;62:567–575
  108. Neese RA, Siler SQ, Cesar D, Antelo F, Lee D, Misell L, et al.  Advances in the stable isotope-mass spectrometric measurement of DNA synthesis and cell proliferation. Anal Biochem. 2001;298:189–195
  109. Messmer D, Messmer B, Albesiano E, Damle R, Allen SL, Kudalkar P, et al.  Direct measurement of B-CLL cell production and turnover in vivo. Blood. 2002;100:169a; (abstr)
  110. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2002;343:1910–1916
  111. Stilgenbauer S, Lichter P, Dohner H. Genomic aberrations in B cell chronic lymphocytic leukemia. In:  Cheson BD editors. Chronic Lymphoid Leukemias. New York, NY: Dekker; 2001;p. 353–376
  112. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99:15524–15529
  113. Oscier DG, Thompsett A, Zhu D, Stevenson FK. Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood. 1997;89:4153–4160
  114. Desmaze C, Soria JC, Freulet MA-Marriere, Mathieu N, Sabatier L. Telomere-driven genomic instability in cancer cells. Cancer Lett. 2003;194:173–182
  115. Malisan F, Fluckiger AC, Ho S, Guret C, Banchereau J, Martinez-Valdez H. B-chronic lymphocytic leukemias can undergo isotype switching in vivo and can be induced to differentiate and switch in vitro. Blood. 1996;87:717–724
  116. Bentz M, Huck K, du Manoir S, Joos S, Werner CA, Fischer K, et al.  Comparative genomic hybridization in chronic B-cell leukemias shows a high incidence of chromosomal gains and losses. Blood. 1995;85:3610–3618
  117. Novak U, Oppliger Leibundgut E, Hager J, Muhlematter D, Jotterand M, Besse C, et al.  A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:1787–1794
  118. Ottaggio L, Viaggi S, Zunino A, Zupo S, Rossi E, Spriano M, et al.  Chromosome aberrations evaluated by comparative genomic hybridization in B-cell chronic lymphocytic leukemia (Correlation with CD38 expression). Haematologica. 2003;88:769–777
  119. Kuppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene. 2001;20:5580–5594
  120. Mann DL, DeSantis P, Mark G, Pfeifer A, Newman M, Gibbs N, et al.  HTLV-I-associated B-cell CLL (Indirect role for retrovirus in leukemogenesis). Science. 1987;236:1103–1106
  121. Liu YJ, Johnson GD, Gordon J, MacLennan IC. Germinal centres in T-cell-dependent antibody responses. Immunol Today. 1992;13:17–21
  122. Hardy RR, Hayakawa K. B cell development pathways. Annu Rev Immunol. 2001;19:595–621
  123. Klein U, Goossens T, Fischer M, Kanzler H, Braeuninger A, Rajewsky K, et al.  Somatic hypermutation in normal and transformed human B cells. Immunol Rev. 1988;162:261–280
  124. Spencer J, Perry ME, Dunn-Walters DK. Human marginal-zone B cells. Immunol Today. 1998;19:421–426
  125. Martin F, Oliver AM, Kearney JF. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity. 2001;14:617–629
  126. Martin F, Kearney JF. Marginal-zone B cells. Positive selection from newly formed to marginal zone B cells depends on the rate of clonal production, CD19, and btk. Nat Rev Immunol. 2002;2:323–335
  127. Chen X, Martin F, Forbush KA, Perlmutter RM, Kearney JF. Evidence for selection of a population of multi-reactive B cells into the splenic marginal zone. Int Immunol. 1997;9:27–41
  128. Dono M, Zupo S, Leanza N, Melioli G, Fogli M, Melagrana A, et al.  Heterogeneity of tonsillar subepithelial B lymphocytes, the splenic marginal zone equivalents. J Immunol. 2000;164:5596–5604
  129. Dono M, Zupo S, Colombo M, Massara R, Gaidano GL, Taborelli G, et al.  The human marginal zone B cell. Ann NY Acad Sci. 2003;987:117–124
  130. Fagarasan S, Honjo T. Intestinal IgA synthesis (Regulation of front-line body defences). Nat Rev Immunol. 2003;3:63–72
  131. Liu YJ, Barthelemy C, de Bouteiller O, Arpin C, Durand I, Banchereau J. Memory B cells from human tonsils colonize mucosal epithelium and directly present antigen to T cells by rapid up-regulation of B7–1 and B7–2. Immunity. 1995;2:239–248
  132. Kantor AB, Stall AM, Adams S, Herzenberg LA, Herzenberg LA. Differential development of progenitor activity for three B-cell lineages. Proc Natl Acad Sci USA. 1992;89:3320–3324
  133. Nisitani S, Murakami M, Akamizu T, Okino T, Ohmori K, Mori T, et al.  Preferential localization of human CD5+ B cells in the peritoneal cavity. Scand J Immunol. 1997;46:541–545
  134. Dammers PM, Visser A, Popa ER, Nieuwenhuis P, Kroese FG. Most marginal zone B cells in rat express germline encoded Ig VH genes and are ligand selected. J Immunol. 2000;165:6156–6169
  135. Li Y, Li H, Weigert M. Autoreactive B cells in the marginal zone that express dual receptors. J Exp Med. 2002;195:181–188
  136. Widhopf GF, Brinson DC, Kipps TJ, Tighe H. Transgenic expression of a human polyreactive Ig expressed in chronic lymphocytic leukemia generates memory-type B cells that respond to nonspecific immune activation. J Immunol. 2004;172:2092–2099
  137. Seidl KJ, MacKenzie JD, Wang D, Kantor AB, Kabat EA, Herzenberg LA. Frequent occurrence of identical heavy and light chain Ig rearrangements. Int Immunol. 1997;9:689–702
  138. Messmer BT, Albesiano E, Messmer D, Chiorazzi N. The pattern and distribution of immunoglobulin VH gene mutations in chronic lymphocytic leukemia are consistent with the canonical somatic hypermutation process. Blood. 2004;103:3490–3495
  139. Zelenetz AD, Chen TT, Levy R. Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection. J Exp Med. 1992;176:1137–1148
  140. Capello D, Fais F, Vivenza D, Migliaretti G, Chiorazzi N, Gaidano G, et al.  Identification of three subgroups of B cell chronic lymphocytic leukemia based upon mutations of BCL-6 and IgV genes. Leukemia. 2000;14:811–815
  141. Pasqualucci L, Neri A, Baldini L, Dalla-Favera R, Migliazza A. BCL-6 mutations are associated with immunoglobulin variable heavy chain mutations in B-cell chronic lymphocytic leukemia. Cancer Res. 2000;60:5644–5648
  142. Sahota SS, Davis Z, Hamblin TJ, Stevenson FK. Somatic mutation of bcl-6 genes can occur in the absence of V(H) mutations in chronic lymphocytic leukemia. Blood. 2000;95:3534–3540
  143. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, et al  Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625–1638
  144. Wakai M, Hashimoto S, Omata M, Sthoeger ZM, Allen SL, Lichtman SM, et al.  IgG+, CD5+ human chronic lymphocytic leukemia B cells. Production of IgG antibodies that exhibit diminished autoreactivity and IgG subclass skewing. Autoimmunity. 1994;19:39–48
  145. Hashimoto S, Dono M, Wakai M, Allen SL, Lichtman SM, Schulman P, et al.  Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells. J Exp Med. 1995;181:1507–1517
  146. Casola S, Otipoby KL, Alimzhanov M, Humme S, Uyttersprot N, Kutok JL, et al.  B cell receptor signal strength determines B cell fate. Nat Immunol. 2004;5:317–327
  147. Ikematsu H, Kasaian MT, Schettino EW, Casali P. Structural analysis of the VH-D-JH segments of human polyreactive IgG mAb. Evidence for somatic selection. J Immunol. 1993;151:3604–3616
  148. Rawstron AC, Green MJ, Kuzmicki A, Kennedy B, Fenton JA, Evans PA, et al.  Monoclonal B lymphocytes with the characteristics of “indolent” chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood. 2002;100:635–639
  149. Ghia P, Prato G, Scielzo C, Stella S, Geuna M, Guida G, et al.  Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood. 2004;103:2337–2342
  150. Rawstron AC, Yuille MR, Fuller J, Cullen M, Kennedy B, Richards SJ, et al.  Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood. 2002;100:2289–2290
  151. Kipps TJ. The CD5 B cell. Adv Immunol. 1989;47:117–185
  152. Dono M, Zupo S, Burgio VL, Augliera A, Tacchetti C, Favre A, et al.  Phenotypic and functional characterization of human tonsillar subepithelial (SE) B cells. Ann N Y Acad Sci. 1997;815:171–181
  153. Dono M, Zupo S, Massara R, Ferrini S, Melagrana A, Chiorazzi N, et al.  In vitro stimulation of human tonsillar subepithelial B cells (Requirement for interaction with activated T cells). Eur J Immunol. 2001;31:752–756
  154. Dono M, Zupo S, Grossi CE, Chiorazzi N, Ferrarini M. Subepithelial B cells of the human tonsil. Chem Immunol. 1997;67:58–69
  155. Ghia P, Caligaris-Cappio F. The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. Adv Cancer Res. 2000;79:157–173

☆ Supported in part by RO1 Grants No. CA 81554 and CA 87956 from the National Cancer Institute and a General Clinical Research Center Grant (M01 RR018535) from the National Center for Research Resources, the Associazione Italian Ricerca sul Cancro (AIRC), and MURST. The Peter J. Sharp Foundation, The Marks Family Foundation, the Jean Walton Fund for Lymphoma & Myeloma Research, and the Joseph Eletto Leukemia Research Fund also provided support for these studies.

PII: S0037-1963(04)00090-3

doi: 10.1053/j.seminhematol.2004.05.003

Seminars in Hematology
Volume 41, Issue 3 , Pages 207-223 , July 2004

Article Tools

* Image Usage & Resolution